A new study has revealed how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels.  

By tracking germinal-centre (GC) activity and individual secreted antibody clonotypes for up to six months, researchers uncovered how vaccination drives the evolution and diversification of immune responses.  

The findings offer new insights into how mRNA technology could help address a key challenge in influenza prevention: generating broader antibody responses against a constantly evolving virus. 

The study was conducted by researchers from Korea University College of Medicine, Republic of Korea, led by Associate Professor Jiwon Lee in the Department of Convergence Medicine and the Vaccine Innovation Center, in collaboration with Professor Ali Ellebedy and his group at Washington University in St Louis, USA.  

The study evaluated the investigational quadrivalent mRNA-1010 vaccine against the licensed Fluarix vaccine. It followed 75 healthy adults aged 20–50 years across two influenza seasons, with 38 receiving mRNA-1010 and 37 receiving Fluarix. Blood samples were collected through 26 weeks, while a subset underwent ultrasound-guided fine-needle aspiration of draining axillary lymph nodes to assess germinal-centre responses. 

Researchers combined flow cytometry, ELISpot, single-cell RNA sequencing and B-cell receptor sequencing, serum IgG proteomics, and antibody binding and neutralisation assays to comprehensively profile immune responses. 

Broader antibody binding 

They found that the mRNA vaccine elicited a substantially more diverse and broader serum antibody repertoire than Fluarix. Most notably, influenza-specific GC responses persisted for up to 26 weeks in five of 13 mRNA-1010 recipients, while persistent GCs were not detected among Fluarix recipients. The vaccine also increased the diversity of the serum IgG repertoire and promoted diversification of pre-existing B-cell lineages through somatic hypermutation.  

These changes were associated with broader antibody binding across antigenically diverse influenza strains and significantly greater increases in neutralisation titres against 11 of 13 A/H1N1 viruses tested.  

A key strength of the study was Ig-Seq, a mass-spectrometry-based technology that identifies individual antibody clonotypes circulating in the blood after vaccination. Together with B-cell sequencing, this molecular-level approach revealed not only the magnitude of the antibody response, but also which antibody lineages emerged, expanded, and diversified after vaccination.